198 related articles for article (PubMed ID: 17509165)
41. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry.
Niikura N; Tomotaki A; Miyata H; Iwamoto T; Kawai M; Anan K; Hayashi N; Aogi K; Ishida T; Masuoka H; Iijima K; Masuda S; Tsugawa K; Kinoshita T; Nakamura S; Tokuda Y
Ann Oncol; 2016 Mar; 27(3):480-7. PubMed ID: 26704052
[TBL] [Abstract][Full Text] [Related]
42. A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers.
Yerushalmi R; Hayes MM; Gelmon KA; Chia S; Bajdik C; Norris B; Speers C; Hassell P; O'Reilly SE; Allan S; Shenkier TN
Clin Breast Cancer; 2009 Aug; 9(3):166-72. PubMed ID: 19661040
[TBL] [Abstract][Full Text] [Related]
43. Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status.
Piper GL; Patel NA; Patel JA; Malay MB; Julian TB
Am Surg; 2004 Dec; 70(12):1103-6. PubMed ID: 15663054
[TBL] [Abstract][Full Text] [Related]
44. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.
Yu KD; Liu GY; Di GH; Wu J; Lu JS; Shen KW; Shen ZZ; Shao ZM
Breast; 2007 Jun; 16(3):307-15. PubMed ID: 17293115
[TBL] [Abstract][Full Text] [Related]
45. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
Guarneri V; Broglio K; Kau SW; Cristofanilli M; Buzdar AU; Valero V; Buchholz T; Meric F; Middleton L; Hortobagyi GN; Gonzalez-Angulo AM
J Clin Oncol; 2006 Mar; 24(7):1037-44. PubMed ID: 16505422
[TBL] [Abstract][Full Text] [Related]
46. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases.
Aurilio G; Disalvatore D; Pruneri G; Bagnardi V; Viale G; Curigliano G; Adamoli L; Munzone E; Sciandivasci A; De Vita F; Goldhirsch A; Nolè F
Eur J Cancer; 2014 Jan; 50(2):277-89. PubMed ID: 24269135
[TBL] [Abstract][Full Text] [Related]
47. Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.
Li AQ; Zhou SL; Li M; Xu Y; Shui RH; Yu BH; Yang WT
PLoS One; 2015; 10(5):e0125067. PubMed ID: 25938238
[TBL] [Abstract][Full Text] [Related]
48. Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study).
Takada M; Ishiguro H; Nagai S; Ohtani S; Kawabata H; Yanagita Y; Hozumi Y; Shimizu C; Takao S; Sato N; Kosaka Y; Sagara Y; Iwata H; Ohno S; Kuroi K; Masuda N; Yamashiro H; Sugimoto M; Kondo M; Naito Y; Sasano H; Inamoto T; Morita S; Toi M
Breast Cancer Res Treat; 2014 May; 145(1):143-53. PubMed ID: 24682674
[TBL] [Abstract][Full Text] [Related]
49. Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer.
Chan M; Chang MC; González R; Lategan B; del Barco E; Vera-Badillo F; Quesada P; Goldstein R; Cruz I; Ocana A; Cruz JJ; Amir E
PLoS One; 2015; 10(7):e0132449. PubMed ID: 26161666
[TBL] [Abstract][Full Text] [Related]
50. Expression of organic anion-transporting polypeptide 1A2 and organic cation transporter 6 as a predictor of pathologic response to neoadjuvant chemotherapy in triple negative breast cancer.
Hashimoto Y; Tatsumi S; Takeda R; Naka A; Ogane N; Kameda Y; Kawachi K; Shimizu S; Sakai M; Kamoshida S
Breast Cancer Res Treat; 2014 May; 145(1):101-11. PubMed ID: 24671357
[TBL] [Abstract][Full Text] [Related]
51. Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors.
Nakamura R; Yamamoto N; Shiina N; Miyaki T; Ikebe D; Itami M; Shida T; Miyazaki M
Breast; 2016 Apr; 26():141-7. PubMed ID: 26732051
[TBL] [Abstract][Full Text] [Related]
52. Impact of progesterone receptor status on response to neoadjuvant chemotherapy in estrogen receptor-positive breast cancer patients.
Boland MR; Ryan ÉJ; Nugent T; Gilroy D; Kelly ME; Kennedy J; Maguire A; Alazawi D; Boyle TJ; Connolly EM
J Surg Oncol; 2020 Oct; 122(5):861-868. PubMed ID: 32613608
[TBL] [Abstract][Full Text] [Related]
53. ER, PgR, HER-2, Ki-67, topoisomerase IIα, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.
Li XR; Liu M; Zhang YJ; Wang JD; Zheng YQ; Li J; Ma B; Song X
Med Oncol; 2011 Dec; 28 Suppl 1():S48-54. PubMed ID: 20872186
[TBL] [Abstract][Full Text] [Related]
54. [Correlations between hormonal receptor and HER2 status or nuclear grades and response rate in breast cancer treated with neoadjuvant chemotherapy of docetaxel alone].
Mimae T; Taira N; Ohsumi S; Takabatake D; Takashima S; Aogi K; Takashima S; Nishimura R
Gan To Kagaku Ryoho; 2009 Apr; 36(4):619-22. PubMed ID: 19381035
[TBL] [Abstract][Full Text] [Related]
55. Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy: distinct patterns of response according to ER expression.
Moon HG; Im SA; Han W; Oh DY; Han SW; Keam B; Park IA; Chang JM; Moon WK; Cho N; Noh DY
Breast Cancer Res Treat; 2012 Aug; 134(3):1133-40. PubMed ID: 22752292
[TBL] [Abstract][Full Text] [Related]
56. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.
Colleoni M; Viale G; Zahrieh D; Bottiglieri L; Gelber RD; Veronesi P; Balduzzi A; Torrisi R; Luini A; Intra M; Dellapasqua S; Cardillo A; Ghisini R; Peruzzotti G; Goldhirsch A
Ann Oncol; 2008 Mar; 19(3):465-72. PubMed ID: 17986623
[TBL] [Abstract][Full Text] [Related]
57. Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy.
Chic N; Schettini F; Brasó-Maristany F; Sanfeliu E; Adamo B; Vidal M; Martínez D; Galván P; González-Farré B; Cortés J; Gavilá J; Saura C; Oliveira M; Pernas S; Martínez-Sáez O; Soberino J; Ciruelos E; Carey LA; Muñoz M; Perou CM; Pascual T; Bellet M; Prat A
EBioMedicine; 2021 Jul; 69():103451. PubMed ID: 34161883
[TBL] [Abstract][Full Text] [Related]
58. Potential impact of the 70-gene signature in the choice of adjuvant systemic treatment for ER positive, HER2 negative tumors: a single institution experience.
Torrisi R; Garcia-Etienne CA; Losurdo A; Morenghi E; Di Tommaso L; Gatzemeier W; Sagona A; Fernandes B; Rossetti C; Eboli M; Rubino A; Barbieri E; Andreoli C; Orefice S; Gandini C; Rota S; Zuradelli M; Masci G; Santoro A; Tinterri C
Breast; 2013 Aug; 22(4):419-24. PubMed ID: 23643803
[TBL] [Abstract][Full Text] [Related]
59. Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study.
Ethier JL; Ocaña A; Rodríguez Lescure A; Ruíz A; Alba E; Calvo L; Ruíz-Borrego M; Santaballa A; Rodríguez CA; Crespo C; Ramos M; Gracia Marco J; Lluch A; Álvarez I; Casas M; Sánchez-Aragó M; Carrasco E; Caballero R; Amir E; Martin M
Eur J Cancer; 2018 May; 94():199-205. PubMed ID: 29573665
[TBL] [Abstract][Full Text] [Related]
60. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials.
Fontanella C; Lederer B; Gade S; Vanoppen M; Blohmer JU; Costa SD; Denkert C; Eidtmann H; Gerber B; Hanusch C; Hilfrich J; Huober J; Schneeweiss A; Paepke S; Jackisch C; Mehta K; Nekljudova V; Untch M; Neven P; von Minckwitz G; Loibl S
Breast Cancer Res Treat; 2015 Feb; 150(1):127-39. PubMed ID: 25677740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
